Polycyclic THRβ Agonist Composition for Metabolic Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective thyroid hormone β receptor agonists for treating and/or preventing diseases regulated by thyroid hormone receptors, particularly in conditions such as nonalcoholic fatty liver disease, dyslipidemia, and atherosclerosis.
Innovation Solution
Development of polycyclic compounds as thyroid hormone β receptor agonists, specifically compounds of formula (1) and their pharmaceutically acceptable forms, which can be synthesized through various chemical reactions involving radical initiators and bases, and are designed to address specific technical challenges in their synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for treating diseases regulated by thyroid hormone receptors, then existing treatment options are available, but effective thyroid hormone β receptor agonists are lacking
Solution Approach 1:
The patent segments the thyroid hormone receptor agonist activity into two distinct subtypes: THRα agonists and THRβ agonists. By designing compounds that selectively activate THRβ receptors rather than THRα, the invention provides targeted therapy for metabolic diseases while avoiding off-target effects, thus resolving the contradiction between therapeutic reliability and receptor subtype versatility
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of thyroid hormone analogs to optimize their selectivity for THRβ receptors. Through systematic variation of molecular parameters (such as substituent groups on the aromatic rings), the invention achieves compounds with enhanced THRβ agonist activity while maintaining or reducing THRα activity, thereby addressing the lack of effective THRβ-specific agonists
2Reliability
If polycyclic compounds are developed as THRβ agonists, then therapeutic benefits for metabolic diseases are achieved, but synthesis complexity increases
Solution Approach 1:
The patent applies preliminary action by first establishing a core polycyclic structural framework that inherently provides THRβ agonist activity. Once this core structure is developed and validated, various substituent groups can be systematically added through relatively straightforward chemical reactions. This approach allows the complex therapeutic activity to be achieved through incremental modifications rather than de novo synthesis of entirely complex molecules
Solution Approach 2:
The patent creates a universal polycyclic core structure that serves multiple functions: it provides the essential THRβ agonist activity, allows for systematic optimization of pharmacokinetic properties, and enables the development of a series of related compounds with different specific activities. This multi-functional core structure reduces overall synthesis complexity by serving as a versatile platform for generating multiple therapeutic candidates
Data Source
AI summary
Provided are a polycyclic thyroid hormone β receptor agonist and the use thereof. Specifically, the present invention relates to a compound as represented by formula (1) or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The compound or pharmaceutical composition can be used for the preparation of a drug for preventing, treating or alleviating diseases regulated by the thyroid hormone β receptor.